



Thomas Jefferson University  
Jefferson Digital Commons

---

Department of Medical Oncology Faculty Papers

Department of Medical Oncology

---

11-1-2016

## Symptom Clusters.

Andrea M. Barsevick

Thomas Jefferson University, [andrea.barsevick@jefferson.edu](mailto:andrea.barsevick@jefferson.edu)

### [Let us know how access to this document benefits you](#)

Follow this and additional works at: <https://jdc.jefferson.edu/medoncfp>

 Part of the [Oncology Commons](#)

---

#### Recommended Citation

Barsevick, Andrea M., "Symptom Clusters." (2016). *Department of Medical Oncology Faculty Papers*. Paper 58.

<https://jdc.jefferson.edu/medoncfp/58>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

**Defining the Symptom Cluster: How Far Have We Come?**

Andrea Barsevick, PhD, RN, AOCN, FAAN

Professor

Thomas Jefferson University

Department of Medical Oncology

Sidney Kimmel Cancer Center

Philadelphia PA

Corresponding Author: Andrea Barsevick, 834 Chestnut Street, Suite 314, Philadelphia PA 19107;

[andrea.barsevick@jefferson.edu](mailto:andrea.barsevick@jefferson.edu); Phone: 215-503-4623

**Abstract**

**Objective:** To examine the evolution of the concept of the symptom cluster through literature synthesis and identification of knowledge gaps.

**Data source:** Published literature

**Conclusion:** A robust body of research has developed showing that clusters of symptoms can be identified empirically with modest evidence of convergence across methods. The science would benefit from a coordinated effort of qualitative studies to ensure that appropriate symptoms are evaluated; empirical symptom cluster identification studies building upon qualitative work; and subgroup identification studies based on empirically defined symptom clusters.

**Implications for Nursing Practice:** Work is needed to demonstrate the value of symptom cluster identification in guiding symptom assessment and management for cancer patients and survivors.

**Key words:** symptom cluster, cancer, cancer-related symptoms

Following the UCSF Symptom Management Group challenge to consider the concept of the “symptom cluster”<sup>1</sup> and a state of the science lecture and paper on the symptom cluster in cancer<sup>2</sup>, more recent publications have examined conceptual and methodological issues in defining symptom clusters<sup>3-12</sup>. For this article, a literature search of PubMed from 2008 to 2015 was conducted and reference lists of relevant publications were also scanned for additional publications. This article examines the evolution over the past 10 years of the concept of the symptom cluster including its definition, related theoretical concepts, methods of identification, stability of clusters, and identification of symptom cluster subgroups. The literature is synthesized and knowledge gaps are assessed as a basis for future research.

### **Definition of a Symptom Cluster**

A symptom cluster has been defined as a stable group of concurrent symptoms that are related to one another and distinct from other symptom clusters<sup>13</sup>. Symptoms in a cluster may be related through a common etiology or mechanism, shared variance, or a common outcome<sup>3</sup>. Stability of clusters could relate to consistency of results across clustering techniques, consistency within cancer populations, or stability over time. To date, no firm conclusions have been drawn about the minimum number of symptoms required to form a cluster; two<sup>1,14</sup> or three symptoms<sup>13</sup> have been proposed. The dictionary defines a cluster as “a number of things of the same kind held together; a group of things”<sup>15</sup>. The actual number of things required is not specified; however, the use of the word “group” carries the implication that it is more than two.

However, there are arguments in favor of including symptom pairs in the definition of a symptom cluster. In two clinical studies in advanced cancer patients, a gastro-intestinal symptom cluster was determined to be made up of two symptoms, nausea and vomiting<sup>16,17</sup>. In a large sample of advanced cancer patients, anxiety-depression was identified as a cluster across three different methods of analysis<sup>18,19</sup>. Given the presence of clinically and statistically meaningful symptom pairs and the potential for others, it makes sense to include symptom pairs in the definition of a symptom cluster. Another reason to consider symptom pairs as clusters is that the number and type of symptoms observed in a cluster is

reflective of the number and type of symptoms that were measured. Measuring a larger number of related symptoms is likely to increase the number of symptoms included in a particular cluster. When fewer symptoms are measured, a symptom pair could be a proxy for a cluster with more symptoms. Including symptom pairs in the definition of a cluster provides an opportunity for a more complete description of symptom clusters in a specific context.

On the other side of this issue are questions about when a symptom cluster should be considered complete. As noted above, one determinant of the number of symptoms comprising a cluster is the number and relevance of the symptoms that are measured. Other determinants include characteristics of specific cancers (such as, cough and breathlessness associated with lung cancer)<sup>20,21</sup>, treatment modalities (neuropathy related to neurotoxic chemotherapy), and demographics (a body image cluster in women with gynecological cancers)<sup>22</sup>. Acknowledging these influences, experts have begun to advocate for agreement about a core set of symptoms to be measured across all patients<sup>23,24</sup> as well as consideration of symptom clusters specific to disease<sup>25,26</sup> and treatment types<sup>27</sup>. This issue is described more fully in the paper on assessment of multiple co-occurring symptoms<sup>(28)</sup>.

### **Related Theoretical Concepts**

Across symptom management theories and models, the addition of the concepts of interaction<sup>29</sup>, time<sup>30</sup>, and mechanism<sup>31</sup> have proven to be important constructs guiding our scientific understanding of the symptom cluster. As the science of symptom management has developed, the theories and models used to describe symptom clusters have expanded to incorporate explicit components. The Theory of Symptom Management, proposed three components originally: the symptoms experience (addressing single or multiple symptoms); symptom management; and outcomes<sup>1</sup>. Later, this theory was expanded to include personal, health-illness, and environmental contexts of symptoms<sup>32</sup>. The Theory of Unpleasant Symptoms explicitly described the potential for interaction and/or synergy among multiple symptoms<sup>29</sup>. Through a linear presentation of antecedents, symptoms, and outcomes, it suggested but did not explicitly identify a time component. Later theoretical models expanded the time component, recognizing that symptoms can vary considerably over time and that variability in one symptom can influence other

symptoms<sup>33,34</sup>. One model, The Symptom Interaction Framework, explicitly identified underlying symptom “mechanisms” to describe alterations in process or function that could explain the presence of a group of symptoms<sup>31</sup>; mechanisms could be biological, psychological, social, or behavioral.

### **Methods of Identification of Symptom Clusters**

Qualitative methods allow for the exploration of the breadth and complexity of related symptoms. Four qualitative studies identified symptom clusters (table 1)<sup>20-22,35</sup>. Women with gynecological cancers identified the symptoms of tiredness, sleeplessness, pain, depression, and weakness as the most common cluster experienced by all participants over one year, irrespective of treatment<sup>22</sup>. Three other symptom clusters were identified in this research, all related to chemotherapy (body image, GI and neuropathy). In a longitudinal qualitative study of symptoms related to lung cancer, a subset of respiratory symptoms including cough, breathlessness, and fatigue were highlighted as co-occurring, influencing one another, and triggering other symptoms such as anxiety, depression, pain, and sleep disturbance<sup>21</sup>. The investigators did not discuss why the triggered symptoms were not part of the cluster. In another lung cancer sample, the core symptoms of fatigue, pain, cough, and breathlessness were associated and affected one another synergistically<sup>20</sup>. However, the investigators noted that participants often focused on individual symptoms and not all symptoms were given equal weight. In a study of chemotherapy-induced nausea, the investigators explored the possibility that the term nausea could represent a cluster of symptoms<sup>35</sup>. They concluded that the nausea experience included a cluster of symptoms that was unique to each individual. Although the research identified a group of co-occurring symptoms that were considered separate but related to nausea (vomiting, taste changes, appetite changes, and fatigue), the investigators did not identify this as a symptom cluster. More rigorous qualitative research is needed to ensure that symptom clusters identified through patient narrative support or challenge the current definition of a symptom cluster.

#### ***A priori* Identification**

In oncology symptom research, symptom clusters have been identified using two different methods: 1) they have been specified “*a priori*”, meaning formed or conceived beforehand; or 2) they

have been identified using empirically, based on observation (also called “de novo”) methods<sup>3</sup>. *A priori* refers to symptoms selected as a cluster based on patient qualitative experience, clinical observation of symptom co-occurrence, or research hypotheses about the relationships among symptoms. Symptom clusters identified in qualitative studies could be considered *a priori* if the individuals being studied determine the symptom selection; alternatively, they could be considered empirical if the clusters are derived through qualitative data analysis.

Quantitative research has been used to study *a priori* symptom clusters. In animal studies, a group of behaviors (asthenia, lethargy, anorexia, weakness, and sleep disturbance) were observed that became known as “sickness behavior,” a syndrome thought to be the result of inflammatory processes induced by disease or trauma<sup>36,37</sup>. This syndrome closely resembles the cluster of symptoms commonly reported by humans in the context of cancer and its treatment that may include fatigue, sleep disturbance, pain, depression, and mental confusion. The similarities between human symptoms and animal behaviors resulted in many investigations in which variations on this group of symptoms were evaluated as *a priori* symptom clusters<sup>30,38-43</sup>.

*A priori* symptom clusters have included variations on the symptoms of fatigue, insomnia, pain, and depressed mood that are related to sickness behaviors (table 2)<sup>30,38-44</sup>. Quantitative studies have demonstrated that these clusters meet two criteria defining a cluster: symptoms are related to one another and have a common influence on outcomes. Most studies used analytic techniques such as correlation, path analysis, structural equation modeling, or other multivariate methods to examine the relationships among a group of symptoms. One study showed that fatigue, sleep disturbance, and depression in breast cancer patients were correlated at each study point; and path analysis showed that symptom severity at each time point predicted severity of the same symptom at subsequent time points with the exception that earlier fatigue predicted later depression in pre-menopausal women<sup>38</sup>. Another study examined temporal changes in daily symptoms (fatigue sleep disturbance, and depressed mood) selected *a priori* in women with gynecological cancers and found that greater sleep disturbance was associated earlier peak fatigue, and higher levels of fatigue predicted later depressed mood<sup>30</sup>. Another study modeled fatigue as a latent

variable directly influenced by pain, depressed mood and insomnia<sup>43</sup>. Results showed direct effects among all four symptoms as well as mediating effects: the effect of depressed mood on pain was mediated by insomnia; and the effect of depressed mood on fatigue was mediated by insomnia and pain.

The effect of a presumed symptom cluster on outcomes has also been examined. For example, multiple regression analysis showed that the cluster of pain, fatigue, insomnia, and mood disturbance predicted performance status and quality of life in elderly cancer patients<sup>39</sup>. In another study, pain, the cluster of fatigue, sleep disturbance, and distress in lung cancer surgery patients was negatively related to performance status and quality of life<sup>41</sup>. Only one study examined how related symptoms influenced outcomes. In a cross-sectional study of fatigue, insomnia, depression, and pain, a cluster was defined as two or more symptoms directly related to each other and indirectly related to functional performance (dependent variable)<sup>44</sup>. Path analysis revealed seven indirect symptom paths to functional performance for pain and three paths for insomnia which the investigators characterized as synergy among symptoms.

### **Empirical Identification**

The selection of an *a priori* symptom cluster does not settle the issue of the completeness of a cluster or the number of symptoms that are or should be included. It is possible that other symptoms could be part of the cluster but were left out because of *a priori* selection of symptoms. To address the completeness issue, an alternative approach has been to use statistical procedures to select and group symptoms from a larger population of symptoms. Thus, an empirically determined symptom cluster is a group of symptoms derived from a larger pool of symptoms using statistical procedures (table 3)<sup>7,16,45-58</sup>. In this methodology, research participants rate a group of symptoms that are relevant to their situation. A variety of statistical methods such as principal components analysis, common factor analysis, or cluster analysis are used to select clusters from the larger pool of symptoms.

Principal Components Analysis (PCA), a type of exploratory factor analysis, is a descriptive data reduction method based on total variance<sup>59</sup> that combines a larger number of variables into smaller clusters that are unique and stable. This method does not presume a theoretical basis or underlying connection among the symptoms within each cluster. PCA has been the method most commonly used



for symptom clustering<sup>16,19,54,58,60</sup>. For example two studies of advanced cancer patients used PCA to identify symptom clusters using the Edmonton Symptom Assessment Scale (ESAS). The first study identified two clusters: cluster 1 included fatigue, drowsiness, nausea, appetite, and dyspnea; cluster 2 comprised anxiety and depression<sup>46,47</sup>. The second study used the ESAS measure, but supplemented it with 13 additional items<sup>16</sup>, identifying four clusters: confusion, neuropsychological, anorexia-cachexia, and gastro-intestinal clusters. In both studies, symptom clusters differed by age, gender, performance status, and/or type of cancer. The difference between the study results could also be related to the symptoms measured. A third study used PCA to identify three clusters in breast cancer patients based on a 32-item symptom scale: emotional, unwell, and gastro-intestinal clusters<sup>50</sup>. The first cluster included similar symptoms to the

Common Factor analysis (CFA) is another type of exploratory factor analysis that examines common variance to determine the latent factors underlying a set of variables and develop and/or test hypotheses about those underlying factors<sup>59</sup>. Two symptom cluster studies using CFA illustrate this point. In a study of breast and prostate cancer patients being treated with radiotherapy, CFA was used to identify symptom clusters in 160 individuals who rated 32 symptoms on the Memorial Symptom Assessment Scale<sup>51</sup>. At the midpoint of treatment, three clusters were identified: a mood-cognitive cluster (difficulty concentrating, feeling nervous, feeling sad, worrying, itching, feeling irritable, skin changes); a sickness behavior cluster (pain, lack of energy, feeling drowsy, difficulty sleeping, sweats); and a treatment-related cluster (urinary problems and diarrhea). In a separate study, 282 women receiving chemotherapy or radiotherapy for breast cancer rated twenty symptoms<sup>52</sup>. Two symptom clusters were identified during treatment: a psycho-neurological cluster (pain, fatigue, insomnia, depressed mood, cognitive disturbance, and hot flashes); and an upper gastro-intestinal cluster (nausea, vomiting, decreased appetite). The “sickness behavior cluster” in the breast and prostate study was similar to the “psycho-neurological cluster in the breast cancer study.

Two things are noteworthy. First, the results provided empirical validation of the “sickness behavior” cluster that was previously identified *a priori*. Secondly, implicit in the naming of the clusters

was a hypothesis about the underlying mechanism. The “sickness behavior” cluster and the “psycho-neurological” cluster both have a hypothesized underlying mechanism of inflammation. Although the symptoms included in each cluster are slightly different, some of the core symptoms are the same, lending modest support to the idea that there is a common mechanism underlying this group of symptoms.

Hierarchical Cluster analysis (HCA) is an empirical method for grouping symptoms or people and separating them from dissimilar groups based on measures of distance, such as Euclidian distance <sup>61</sup>. In a study of 922 advanced cancer patients in a palliative medicine program, HCA was used to group 25 symptoms <sup>53</sup>. Seven clusters were identified: fatigue-anorexia-cachexia, psycho-neurological, upper gastro-intestinal, nausea-vomiting, aero-digestive, debility, and pain clusters. The authors argued that these clusters were likely to be therapeutically important because treatment of one symptom could influence or be influenced by another symptom in the cluster. For example, the pain cluster included both pain and constipation; in advanced cancer, pain is a common problem that is often treated with opioid analgesics that can induce constipation.

### **Stability of Symptom Clusters**

**Consistency across Clustering Techniques.** In a number of studies, investigators have searched for symptom clusters using more than one analytic technique (table 4)<sup>19,60,62-67</sup>. Looking across clustering methods, one can observe both similarities and differences in the number and composition of symptom clusters. A study of 1296 advanced cancer patients illustrated this point <sup>62</sup>. The cluster of anxiety and depression was identified across all three clustering methods (PCA, HCA, and CFA). Two identical clusters also emerged when analyzed with PCA and HCA: one cluster included appetite, nausea, wellbeing, and pain; the other included fatigue, drowsiness, and dyspnea. With CFA, only one additional factor emerged combining all the remaining symptoms into one factor. The investigators concluded that PCA and HCA were in closer agreement than CFA. Another example of agreement between PCA and HCA can be seen in a study of 400 patients with inoperable lung cancer <sup>60</sup>. Three symptom clusters (pain, mood, and respiratory) were consistent across three different methods of analysis: Pearson correlation,

PCA, and HCA. Looking across studies, appetite change, proposed in qualitative research as an additional component of a nausea-vomiting cluster<sup>35</sup>, was confirmed in two empirical analyses<sup>52,56</sup>.

**Consistency within Cancer Populations.** Looking at similar cancer populations, several review papers concluded that there is little consistency of symptom clusters across samples. For example, a review of five breast cancer studies found no cluster consistency across studies<sup>10</sup>. A review of gastrointestinal symptom clusters<sup>11</sup> found that 38 of 40 clusters included different symptoms; and a review of five lung cancer studies showed only nausea/vomiting and a respiratory cluster were common across two studies<sup>9</sup>. In a review of studies of patients with advanced disease, the authors could not formulate a general consensus of symptom clusters due to variability in symptoms assessed, assessment measures used, analytic methods, and patient demographics<sup>12</sup>.

### **Stability over Time**

Over the past decade, evidence has accumulated in support of the stability of symptom clusters over time. Symptoms evaluated with exploratory factor analysis at the middle, end, and 1 month after radiotherapy for breast or prostate cancer showed four relatively similar symptom clusters across time points: mood-cognitive; treatment-related; sickness-behavior; and pain<sup>51</sup>. For breast cancer patients undergoing treatment, a psycho-neurological symptom cluster was observed via common factor analysis prior to treatment; this cluster was repeated during treatment and a gastro-intestinal cluster was also observed<sup>52</sup>. Symptom clusters identified before treatment in women with ovarian cancer were repeated during chemotherapy; additional clusters were observed during treatment that could represent the short- and long-term effects of treatment<sup>49</sup>. These studies and many others provide increasing support for the clustering of symptoms by virtue of their concurrence and stability over time.

### **Antecedents and Consequences**

A better understanding of the antecedents and consequences of a symptom cluster could inform our understanding of who is likely to experience specific clusters and how the clusters influence their quality of life. Cluster composition has been shown to differ by age and gender<sup>47</sup> and by performance status and cancer diagnosis<sup>16</sup> in two different studies. In contrast, another study found no differences in

symptom cluster composition based on demographic or clinical factors<sup>52</sup>. With regard to consequences of symptom clusters, the number of symptom clusters experienced<sup>16</sup> and the presence of a specific symptom cluster<sup>67</sup> were associated with survival/mortality. In addition, more symptoms<sup>41</sup>, more severe symptoms<sup>66</sup>, and the presence of specific clusters<sup>56</sup> have predicted poorer quality of life. More work is needed to point us toward a more robust picture of the demographic and clinical context of specific symptom clusters as well as the likelihood that specific clusters influence important outcomes including quality of life and survival.

### **Identification of Patient Subgroups with a Similar Symptom Experience**

Thus far, we have examined the way in which “symptoms” are related to one another. An alternative approach is to examine differences in the symptoms experience within “subgroups” of individuals (table 5)<sup>68-77</sup>. Regardless of how a symptom cluster has been determined (*a priori* or empirically), there is likely to be variability in how individuals experience the cluster. One method of grouping patients is to create composite symptom scores. Sanford and colleagues<sup>76</sup> selected fatigue, sleep disturbance, depression, anxiety, and confusion as an *a priori* cluster in women undergoing chemotherapy for breast cancer. Participants were assigned to a symptom cluster index group based on the number of abnormal symptom scores at the initial assessment. With the exception of anxiety, the coherence and stability of each symptom cluster group was demonstrated by similar patterns of symptom severity and change over time in all four symptoms. Using a similar methodology to classify groups of breast cancer patients on the basis of fatigue, sleep disturbance, and depression, Liu et al<sup>74</sup> found a similar pattern of symptom cluster groups across time.

Statistical grouping methods have also been used to evaluate groups of individuals to determine the prevalence and pattern of symptoms within cluster groups. Hierarchical Cluster analysis (HCA), previously described as a method for grouping symptoms, has also been used to identify subgroups of individuals with similar symptom patterns; Latent Class Analysis (LCA) has also been used for this purpose. Based on HCA of the most common symptoms (fatigue, pain, dyspnea, and insomnia), lung cancer patients were classified into groups with mild (60%), moderate (28%) or severe (12%) composite

symptom scores<sup>70</sup>. Another study used HCA to evaluate severity patterns of the psycho-neurological symptom cluster (including fatigue, insomnia, pain, depressed mood, and cognitive disturbance) in breast cancer patients to identify four groups: all low symptoms (26%), all high symptoms (24%), low pain-high fatigue (19%), and high pain (30%) groups<sup>73</sup>. In a separate study, breast cancer patients were classified using LCA into subgroups based on symptoms (fatigue, insomnia, pain, and depression); subgroups included all low symptoms (61%), all high symptoms (7%), and low pain-high fatigue (32%)<sup>69</sup>. Despite some variation in results, these studies indicate that groups of cancer patients can be classified according to similarities in their experience of symptom clusters.

### **Stability of Symptom Cluster Subgroups over Time**

There is some evidence that symptom cluster subgroups endure over time. Prior to radiotherapy, men with prostate cancer were classified into four subgroups with similar patterns of fatigue, insomnia, pain, depressed mood, anxiety, and treatment-related symptoms (bowel, urinary, and sexual): all low symptoms; moderate treatment-related symptoms; all high symptoms; and moderately high fatigue, depression, and anxiety with few treatment-related symptoms<sup>68</sup>. Similar groupings were derived after treatment. In breast cancer patients undergoing treatment, before treatment subgroups were replicated during treatment and two new groups emerged: high depressed mood-cognitive disturbance and high fatigue-insomnia groups<sup>73</sup>.

### **Antecedents and Consequences of Symptom Cluster Subgroups**

Symptom cluster subgroups were shown in one study to differ by treatment received, performance status, and education<sup>73</sup>; however, another study observed no differences based on demographic or clinical factors<sup>74</sup>. Considering biomarkers, several investigators were able to differentiate subgroups based on the presence of rare cytokine gene alleles<sup>69</sup>, the additive effects of five immune response genes<sup>75</sup>, or cytokine levels<sup>77</sup>. With regard to outcomes, research has shown that subgroups with more severe symptom clusters had poorer quality of life<sup>70,71</sup>, worse functional status<sup>73</sup>, and increased depression and worse mental quality of life<sup>66</sup>. Continued work in this domain will benefit the identification of subgroups at high risk for potentially damaging effects on patient outcomes.

## **Synthesis and Conclusions**

### **Advances in Defining the Symptom Cluster**

There have been significant advances in symptom cluster science over the past decade. With regard to the definition of a symptom cluster, examples in the literature of clinically meaningful symptom pairs such as nausea-vomiting<sup>16,17</sup> or anxiety-depression<sup>18</sup> add strength to the argument for including symptom pairs within the definition of the symptom cluster. More is to be gained than lost in accepting the more inclusive definition. In addition, several theoretical concepts have been incorporated into symptom models to guide the study of symptom clusters including evaluation of influences of symptoms on one another, examination of cluster stability over time, and determination of underlying mechanisms. An evidence base is developing to support the relevance of these concepts to the science of symptom clusters.

### **Advances in Research and Future Directions**

It is interesting to note that cancer patients and survivors have been able to recognize and articulate groups of inter-related symptoms that impacted their quality of life. Symptom cluster science could benefit from more focused qualitative explorations of symptom clusters across the cancer trajectory from diagnosis, through treatment, and into survivorship. Learning from patients and survivors which symptoms co-occur reliably, are most distressing, and/or result in the most interference with functional status and quality of life will better inform quantitative science by ensuring that all relevant symptoms are represented in models. This will also enhance the validity of the quantitative models as representations of the patient-survivor experience. It may also be useful to use qualitative research to validate statistically derived symptom clusters as congruent with patient symptoms experience.

There is now a robust body of research showing that clusters of symptoms can be identified empirically using a variety of statistical methods. There is modest evidence of convergence across empirical clustering methods applied within the same sample. However, there is less evidence of convergence and validation of clusters across similar samples using the same or different analytic strategy. Therefore, replication studies are needed to ensure the reproducibility and usefulness of the

statistically identified symptom cluster in the clinical setting. Looking across methods used in symptom cluster research to date, the science would benefit from a coordinated effort of qualitative studies to ensure that appropriate symptoms are evaluated for clustering; empirical symptom cluster identification studies that build upon that qualitative work; and studies identifying patient subgroups based on empirically defined symptom clusters. This progression would enhance the validity and reproducibility of symptom cluster research.

Scientists have explored demographic, personal, and clinical characteristics associated with symptom clusters and cluster subgroups. There is also research evidence that symptom clusters influence clinical outcomes including quality of life and survival. This information is important for the identification of symptom cluster phenotypes—that is, subgroups with similar symptom patterns, identifying characteristics, and probable outcomes. Continuing work is needed to identify high risk groups (at risk for more severe symptoms and/or worse outcomes) that can be targeted for intervention development and evaluation. Ultimately there is a need to demonstrate the value of symptom cluster identification in guiding symptom assessment and management for cancer patients and survivors.

Table 1. Identification of Symptom Clusters in Qualitative Research

<b>Authors</b>	<b>Sample</b>	<b>Design</b>	<b>Method</b>	<b>Symptom Clusters</b>	<b>Covariates/Outcomes</b>
Lopez, et al. <sup>22</sup>	10 women in U.K. with GYN cancers	Longitudinal: Pre-treatment to 12 months post-treatment  39 interviews	Content Analysis	<ol style="list-style-type: none"> <li>1. Tiredness, sleeplessness, pain, depression, weakness</li> <li>2. Hair loss, ocular changes, body image, identity experience, anxiety</li> <li>3. Nausea, appetite loss, taste changes, bowel function, weight changes, distress</li> <li>4. Numbness-tingling in hands and feet, restlessness, sleeplessness, depression</li> </ol>	Physical symptoms interrelated with depression, uncertainty, body image, and identity as cancer patient.
Maguire, et al. <sup>20</sup>	10 individuals in U.K. with advanced lung cancer reporting 3+ symptoms	Longitudinal: 2 interviews 3-5 weeks apart	Interpretative Phenomenological Analysis (IPA)	<ol style="list-style-type: none"> <li>1. Cough, pain, insomnia</li> <li>2. Breathlessness, appetite loss, weight loss</li> <li>3. Fatigue, nocturia, disrupted sleep</li> </ol>	Detrimental impact on physical functioning
Molassiotis, et al. <sup>21</sup>	17 individuals in U.K. with inoperable lung cancer	Longitudinal: Beginning of treatment, 3, 6, 12 months	IPA	<ol style="list-style-type: none"> <li>1. Cough, breathlessness, fatigue, sleep disturbance, anxiety</li> </ol>	<ul style="list-style-type: none"> <li>• Cough associated with sleeplessness;</li> <li>• Sleeplessness triggered fatigue;</li> <li>• Coughing worsened breathlessness;</li> <li>• Breathlessness triggered anxiety</li> </ul>
Olver, et al. <sup>35</sup>	42 cancer patients in Australia with chemotherapy-induced nausea	Cross-sectional	Thematic analysis	Separate concomitant symptoms experienced with nausea: vomiting, appetite changes, taste changes, fatigue	



Table 2. *A Priori* Identification of Symptom Clusters in Quantitative Research

Authors	Sample	Design	Method	Symptom Clusters	Covariates/Patterns/Outcomes
Cheng, et al. <sup>39</sup>	120 elderly Chinese cancer patients undergoing treatment	Cross-sectional  Symptom Distress Scale (SDS); 4 symptoms selected for analysis	Multiple Regression  Independent variables: symptoms  Dependent variables: functional status, quality of life	Symptom cluster: pain, fatigue, insomnia, mood disturbance	<ul style="list-style-type: none"> <li>• 20% of sample reported any 2 symptoms; 29%; reported any 3 symptoms; 33% reported all 4 symptoms</li> <li>• Low to moderate correlations between symptom pairs</li> <li>• All 4 symptoms had independent effects on quality of life</li> </ul>
Ho, et al. <sup>38</sup>	137 breast cancer patients in U.S. treated with chemotherapy	Longitudinal:  Pre-, post, and 6-8 months  Validated symptom scales	Path Analysis	Symptom cluster: Fatigue, sleep disturbance, depression	<ul style="list-style-type: none"> <li>• All symptoms were correlated at each time point;</li> <li>• Prior symptom severity predicted subsequent severity of same symptom.</li> <li>• In pre-menopausal women, baseline fatigue predicted post-treatment depression; and post-treatment fatigue predicted depression at final follow-up.</li> </ul>
Hoffman, et al. <sup>40</sup>	80 newly diagnosed lung cancer patients in U.S. undergoing chemotherapy	Cross-sectional  Baseline observation  Cancer Symptom Experience Inventory; 3 symptoms selected for analysis	Multinomial log-linear modeling	Symptom cluster: pain, fatigue, insomnia	<ul style="list-style-type: none"> <li>• 3-way interaction among symptoms</li> <li>• Covariates of age, comorbidities, and stage of disease did not improve the model</li> </ul>
Jim, et al. <sup>30</sup>	78 U.S. women with GYN cancers being treated with chemotherapy	Longitudinal:  Daily symptom ratings for 7 days; actigraph for 7 days	Latent Change Scores	Symptom cluster: Fatigue, sleep disturbance, depressed mood	<p>Symptoms occurred in cascade pattern:</p> <ul style="list-style-type: none"> <li>• Higher level of sleep disturbance was associated with earlier peak of fatigue</li> <li>• Higher fatigue level was associated with higher subsequent</li> </ul>

## Symptom Cluster Definition FINAL, 6-13-16

					depressed mood.
Lin, et al. <sup>41</sup>	145 Chinese lung cancer patients post-surgery	Cross-sectional  One week post-surgery  MD Anderson Symptom Inventory (MDASI); 4 symptoms selected based on prevalence and severity	Multiple regression  Independent variables: symptoms  Dependent variable: quality of life	Symptom cluster: fatigue, pain, sleep disturbance, distress	<ul style="list-style-type: none"> <li>• Presence of more symptoms associated with poorer quality of life</li> <li>• In hierarchical regression, fatigue, sleep, and distress accounted for 72% of variance in quality of life</li> </ul>
Oh, et al. <sup>44</sup>	110 South Korean cancer patients undergoing treatment	Cross-sectional  Validated symptom scales	Path Analysis  Symptom cluster defined as two or more symptoms directly related to each other and indirectly related to outcome  Dependent variable: functional performance	Symptom cluster: pain, insomnia, depression, fatigue	<ul style="list-style-type: none"> <li>• 7 indirect paths between pain and functional performance (pain-insomnia, pain-depression, pain-fatigue, pain-depression-fatigue, pain-insomnia-depression-fatigue)</li> <li>• 3 indirect paths between insomnia and functioning (insomnia-depression, insomnia-fatigue, insomnia-depression-fatigue)</li> </ul>
So, et al. <sup>42</sup>	215 Chinese women undergoing treatment for breast cancer in Hong Kong	Cross-sectional  During treatment  Validated symptom scales	Correlation; Structural Equation Modeling (SEM)	Symptom cluster: Fatigue, pain, anxiety, depression	<ul style="list-style-type: none"> <li>• Correlation among symptoms supported existence of symptom cluster</li> <li>• More severe symptoms, treatment with chemotherapy, and lower social support was associated with poorer quality of life</li> </ul>
Stepanski, et al. <sup>43</sup>	11,445 U.S. cancer patients undergoing treatment	Cross-sectional  During treatment  Patient Care	SEM: Test sample and validation sample	Symptom cluster: Fatigue, trouble sleeping, depressed mood, pain	Direct effects: <ul style="list-style-type: none"> <li>• Fatigue, modeled as a latent variable, was influenced by depressed mood, trouble sleeping, and pain.</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

		<p>Monitor</p> <ul style="list-style-type: none"><li>• Validated scale with 86 symptoms</li><li>• 4 symptoms included in analysis</li></ul>			<p>Indirect effects:</p> <ul style="list-style-type: none"><li>• effect of depressed mood on pain mediated by trouble sleeping</li><li>• effect of trouble sleeping on fatigue mediated by pain;</li><li>• effect of depressed mood on fatigue mediated by trouble sleeping and pain.</li></ul> <p>Cross-validation of model was supported by validation sample</p>
--	--	---	--	--	---

Table 3. Empirical Identification of Symptom Clusters

Authors	Sample	Design	Method	Description of Clusters	Covariates/Patterns/Outcomes
Brown, et al. <sup>45</sup>	196 U.S. women 6 months to 5 years post- diagnosis of Non- small cell lung cancer	Cross-sectional  Lung Cancer Symptom Scale (LCS)	Novel strategy for identification of symptom clusters using dummy codes	<ol style="list-style-type: none"> <li>3-symptom cluster: no pattern of symptoms across participants</li> <li>4-symptom cluster: fatigue, shortness of breath, cough, anorexia</li> <li>5-symptom cluster: fatigue shortness of breath, cough, pain, anorexia (reported by 64% of sample)</li> <li>6-symptom cluster: 5-symptom cluster plus hemoptysis</li> </ol>	<ul style="list-style-type: none"> <li>Depressed mood, time since diagnosis, number of comorbidities, and current treatment status were related to overall symptom severity</li> </ul>
Cheung, et al. <sup>46</sup> Cheung, et al. <sup>47</sup>	1,366 Canadian patients with advanced cancer attending palliative care clinics	Cross-sectional  Edmonton Symptom Assessment Scale (ESAS)	Principal Components Analysis (PCA)	<ol style="list-style-type: none"> <li>Fatigue, drowsiness, nausea, appetite, dyspnea</li> <li>Anxiety, depression</li> </ol>	<ul style="list-style-type: none"> <li>Clusters 1 and 2 accounted for 45% and 10% of total variance, respectively;</li> <li>Clusters differed by primary cancer site although cluster 2 was consistent across sites</li> <li>Clusters differed by age and gender: fatigue and drowsiness were included in cluster 1 for younger but not older patients; in men, pain was part of cluster 2; for women, physical and psychological symptoms formed separate clusters</li> </ul>
Gleason, et al. <sup>48</sup>	66 U.S. patients newly diagnosed with brain tumors being treated with radiotherapy	Longitudinal  Pre-treatment, end of treatment  FACT-Brain CESD-Depression	Exploratory Factor Analysis (EFA)	<ol style="list-style-type: none"> <li>Language: difficulty reading, writing, finding works</li> <li>Mood: sadness, anxiety, depressed mood</li> </ol>	<ul style="list-style-type: none"> <li>A 3<sup>rd</sup> factor included only one symptom, so it was dropped</li> <li>Factor structure at end of treatment was consistent with pre-treatment</li> <li>Multidimensional scaling and cluster analysis supported 2-factor structure</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

<p>Huang, et al. <sup>49</sup></p>	<p>111 Chinese ovarian cancer patients undergoing chemotherapy</p>	<p>Longitudinal Pre-, during chemotherapy MSAS</p>	<p>PCA</p>	<p>Pre-treatment 1. Pain-related: Pain, bloating, dizziness 2. Psychological: Nervous, sad, anxious 3. Menopausal: Lack of energy, dry mouth, difficulty sleeping, sweats, lack of appetite, irritation Cycle 1 4. Gastro-intestinal: Nausea, vomiting, weight loss 5. Body image: Hair loss, constipation Cycle 3 6. Neurological: Numbness-tingling, dizziness</p>	<ul style="list-style-type: none"> <li>• Clusters 1, 2, and 3 were stable across time points</li> <li>• The addition of new symptom clusters may be attributed to short- and long-term effects of treatment.</li> </ul>
<p>Jimenez, et al. <sup>16</sup></p>	<p>406 Spanish patients with advanced cancer enrolled in a palliative care program</p>	<p>Cross-sectional ESAS; 13 single symptoms</p>	<p>PCA</p>	<p>1. Confusion cluster: agitation, confusion, urinary incontinence 2. Neuropsychological cluster: Anxiety, depression, insomnia 3. Anorexia-cachexia cluster: Anorexia, weight loss, tiredness 4. GI cluster: Nausea, vomiting</p>	<ul style="list-style-type: none"> <li>• Symptom clusters differed by cancer site, gender, age, and performance status</li> <li>• Survival was related to the number of symptom clusters present</li> </ul>
<p>Kenne Sarenmalm, et al. <sup>50</sup></p>	<p>206 Swedish breast cancer patients undergoing treatment</p>	<p>Longitudinal Diagnosis, weeks 1 and 3, 6 months MSAS</p>	<p>PCA</p>	<p>1. Emotional: sad, nervous, worry, difficulty sleeping, quality of life 2. Unwell: drowsy, dry mouth, appetite loss, irritability, difficulty swallowing, shortness of breath 3. GI: weight loss, taste change, constipation, vomiting, hair loss, nausea</p>	<ul style="list-style-type: none"> <li>• PCA Clusters 1 and 3 were consistent across all time points; cluster 2 was less consistent</li> </ul>
<p>Kim, et al. <sup>51</sup></p>	<p>160 U.S. breast or prostate cancer patients being</p>	<p>Longitudinal Pre-treatment,</p>	<p>EFA</p>	<p>Factor structure at middle of radiotherapy: 1. Mood-cognitive:</p>	<ul style="list-style-type: none"> <li>• Symptom clusters identified at end of treatment and one month later were not identical to mid-</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

	treated with radiotherapy	middle and end of treatment, 1 month later  MSAS		concentration, feeling nervous, sadness, worry, itching, irritability, skin changes 2. Sickness behavior: pain, lack of energy, drowsiness, sleep difficulty, sweating 3. Treatment-related: urinary problems, diarrhea	treatment clusters; however, the mood-cognitive and sickness behavior clusters were very similar.
Kim, et al. <sup>52</sup>	282 U.S. breast cancer patients treated with chemotherapy or radiotherapy	Longitudinal  Pre-treatment, during treatment, end of treatment  20 symptoms (some single items, some validated scales)	Common Factor Analysis (CFA)	Pre-treatment 1. Psycho-neurological: Depressed mood, cognitive disturbance, fatigue insomnia, pain First follow-up 1. Psycho-neurological (hot flashes added) 2. Gastro-intestinal: nausea, vomiting, low appetite Second follow-up 1. Psycho-neurological 2. Gastro-intestinal	<ul style="list-style-type: none"> <li>• Clustering of symptoms was consistent across treatment trajectory</li> <li>• Demographic and clinical variables did not influence clustering</li> </ul>
Kirkova, et al. <sup>7</sup> Walsh, et al. <sup>53</sup>	922 U.S. patients with advanced cancer in palliative care program  Validation sample of 181 patients	Cross-sectional  25 symptoms with prevalence > 15%	Hierarchical Cluster Analysis (HCA)	1. Fatigue-anorexia-cachexia cluster: fatigue, lack of energy, weakness, dry mouth, anorexia, early satiety, taste change, weight loss 2. Neuro-psychological cluster: sleep problems, anxiety, depression 3. Upper GI cluster: dizzy spells, dyspepsia, belching, bloating 4. Nausea-vomiting cluster: nausea, vomiting 5. Aero-digestive cluster: dyspnea, cough, hoarseness, dysphagia 6. Debility cluster: edema, confusion 7. Pain cluster: pain, constipation	<ul style="list-style-type: none"> <li>• Kirkova: Validation study clusters were similar but not identical (8 clusters)</li> </ul>

## Symptom Cluster Definition FINAL, 6-13-16

Molassiotis, et al. <sup>54</sup>	143 patients in U. K. cancer centers	Longitudinal Pre-treatment, 3, 6, 12 months later  MSAS	PCA	Pre-treatment: 1. Nausea, vomiting, bloating 2. Numbness-tingling hands, feet; swelling arms-legs 3. Hair loss; do not like self 4. Shortness of breath, cough 5. Difficulty swallowing, weight loss, low appetite, vomiting, pain 6. Feeling sad, worrying, nervous, difficulty concentrating, dizziness, drowsiness, Irritability, lack of energy	At subsequent time points, PCA used again to determine core symptoms: <ul style="list-style-type: none"> <li>At 3- and 6-month assessments, core symptoms were maintained but new symptoms entered some clusters</li> <li>At 12 months, clusters decreased in number of items</li> </ul> Overall, the six clusters remained relatively consistent over time
Olson, et al. <sup>55</sup>	82 patients in Canada receiving palliative care	Longitudinal 1 month and 1 week before death  ESAS	SEM  Exogenous (background) variables: pain, anxiety, nausea, shortness of breath, drowsiness  Endogenous (dependent): appetite, tiredness, depression, wellbeing	Stable effects across time periods: <ul style="list-style-type: none"> <li>Drowsiness predicted appetite</li> <li>Drowsiness predicted tiredness</li> <li>Anxiety predicted depression</li> </ul>	Conclusion: There were different and changing causal structures underlying connections between symptoms
Pirri, et al. <sup>56</sup>	200 newly diagnosed Australian cancer patients undergoing combined modality treatment	Longitudinal Pre-, on-, post-treatment  EORTC QLQ-C30 Selby quality of life scale	PCA used to identify any symptom cluster that included nausea and vomiting	<ul style="list-style-type: none"> <li>6-factor solution</li> <li>Gastro-intestinal (GI) cluster (nausea, vomiting, appetite loss) at every time point</li> </ul>	<ul style="list-style-type: none"> <li>Controlling for covariates, GI cluster predicted overall quality of life impairment at end of treatment</li> <li>The moderating effects of all 3 symptoms on quality of life was stronger than any single symptom or symptom pair</li> </ul>
Skerman, et al. <sup>57</sup>	219 Australian cancer patients	Longitudinal	CFA	Over time, 5 consistent symptom clusters were characterized:	<ul style="list-style-type: none"> <li>Several symptoms were associated with different clusters</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

	being treated with chemotherapy	Within 1 month of initiating chemotherapy, 6, 12 months later  Rotterdam Symptom Checklist—42 symptoms		<ol style="list-style-type: none"> <li>1. Vasomotor: sweating, hot/cold spells, night sweats</li> <li>2. Oral discomforts: difficulty swallowing, sore throat, sore mouth, pain swallowing</li> <li>3. Upper gastro-intestinal/aero-digestive discomforts: indigestion, heartburn, belching</li> <li>4. Gastro-intestinal toxicities: poor appetite, vomiting, nausea, shivering, stomach pain, trembling</li> <li>5. Musculoskeletal discomforts, lethargy: fatigue, sleepiness, muscle soreness, weakness</li> </ol>	<p>over time: poor appetite, weakness, and fatigue</p> <ul style="list-style-type: none"> <li>• Vasomotor, oral, and musculoskeletal clusters were replicated over time, retaining over 75% of the original symptoms</li> </ul>
Tsai, et al. <sup>58</sup>	427 Taiwanese patients with advanced cancer admitted to a palliative care unit	Cross-sectional  Upon admission  Face-valid symptom reporting scale—15 items	PCA	<ol style="list-style-type: none"> <li>1. Loss of energy: fatigue, weakness</li> <li>2. Poor intake: anorexia, taste changes, dysphagia, constipation, dry mouth</li> <li>3. Autonomic dysfunction: restlessness, heat, dizziness, insomnia, night sweats</li> <li>4. Aero-digestive impairment: nausea, vomiting, abdominal fullness, dyspnea</li> <li>5. Pain</li> </ol>	



Table 4. Comparison of Methods for Identification of Symptom Clusters

Authors	Sample	Design	Method	Clusters or Subgroups	Covariates/Outcomes
Chen, E. <sup>18</sup> Fan, G. <sup>19</sup>	1296 Canadian patients with advanced cancer referred to outpatient palliative care service	Longitudinal  Baseline, 1-, 2-, 4-, 8-, and 12-weeks  ESAS	PCA, HCA, EFA	Baseline: PCA 1. Appetite, nausea, wellbeing, pain 2. Fatigue, drowsiness, dyspnea 3. Anxiety, depression  EFA: 1. Fatigue, drowsiness, dyspnea wellbeing, appetite, pain, nausea, 2. Anxiety, depression  HCA re-dividing cluster 1: 1. Fatigue, drowsiness, dyspnea 2. Appetite, nausea, wellbeing, pain 3. Anxiety, depression	<ul style="list-style-type: none"> <li>• The number and composition of symptom clusters varied over time</li> <li>• Using the same analysis method, clusters were consistent over time</li> <li>• Symptom pairs (anxiety and depression; fatigue and drowsiness) were consistently in the same cluster with shifting of other symptoms over time</li> <li>• Results for PCA and HCA were more consistent across methods than EFA</li> </ul>
Cheville, A. <sup>63,64</sup>	2405 U.S. lung cancer survivors up to 5 years post-diagnosis	Longitudinal: 1, 2, 3, 4, 5 years  LCS; single items: sleep quality; emotion, social, cognitive wellbeing	HCA, EFA, Latent Trait Analysis (LTA)	HCA: 1-5 years 1. Dyspnea, cough, fatigue  EFA 1. Dyspnea, cough, fatigue  LTA: 1. Fatigue, dyspnea, cough 2. Emotional wellbeing, sleep	<ul style="list-style-type: none"> <li>• A single symptom cluster was consistent across analytic methods</li> <li>• Presence of the symptom cluster, each component symptom, and symptom pairs were associated with decreased survival</li> <li>• Differences were small between the capacity of symptom clusters, pairs or individual symptoms to predict survival</li> </ul>
Henoch, I. <sup>60</sup>	400 Swedish newly diagnosed Swedish lung cancer patients	Cross-sectional 1 month post-diagnosis  SDS, EORTC QLQ-C30 (the same 11 items from each	Correlation, PCA, HCA	Correlation: EORTC and SDS  1. Pain cluster: pain, bowel, nausea, appetite, fatigue 2. Mood cluster: insomnia, mood, concentration, outlook 3. Respiratory cluster (SDS only): dyspnea, cough	<ul style="list-style-type: none"> <li>• Clusters were judged to be consistent across measures and analytic methods</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

		scale)		<p>PCA: EORTC and SDS</p> <ol style="list-style-type: none"> <li>1. Pain cluster</li> <li>2. Mood cluster</li> <li>3. Respiratory cluster</li> </ol> <p>HCA: EORTC and SDS</p> <ol style="list-style-type: none"> <li>1. Mood cluster</li> <li>2. Respiratory cluster</li> <li>3. Pain cluster: pain, bowel, nausea</li> <li>4. Appetite, fatigue: closely related to each other and to pain cluster</li> </ol>	
Maliski, S. <sup>65</sup>	402 U.S. men with prostate cancer undergoing treatment	<p>Cross-sectional</p> <p>8-12 months post-treatment</p> <p>PCI-SF: urinary, sexual, bowel dysfunction; SF-36: fatigue, pain, emotional distress</p>	FA, HCA	<p>FA:</p> <ol style="list-style-type: none"> <li>1. Fatigue, emotional distress</li> <li>2. Sexual and bowel dysfunction; pain</li> </ol> <p>[urinary dysfunction loaded equally on both factors]</p> <p>HCA: Subgroups</p> <ol style="list-style-type: none"> <li>1. Most pain, some fatigue, some sexual dysfunction (10%)</li> <li>2. Most urinary and sexual dysfunction (19%)</li> <li>3. Most fatigue, most emotional distress, some sexual dysfunction (14%)</li> <li>4. Most bowel dysfunction, some sexual dysfunction (10%)</li> <li>5. Minimal symptoms (48%)</li> </ol>	<ul style="list-style-type: none"> <li>• Composition of the clusters was not consistent across analytic methods</li> </ul>
Roiland, R. A. <sup>66</sup>	192 U.S. older adult breast cancer survivors	<p>Cross-sectional</p> <p>Baseline data</p> <p>Symptom Bother Scale (37 items)</p>	EFA, CFA SEM	<ol style="list-style-type: none"> <li>1. Musculoskeletal: ache, stiffness, pain, joint pain, weakness, fatigue</li> <li>2. Neurocognitive: balance, dizziness, memory problems, concentration</li> <li>3. Dryness: dry skin, itching, dry mouth, thirst, shortness of breath</li> </ol>	<ul style="list-style-type: none"> <li>• 7-factor solution from EFA had adequate fit in CFA</li> <li>• All 7 clusters were associated with increased depression and poorer quality of life</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

				<ol style="list-style-type: none"> <li>4. Urinary: incontinence, increased urination, decreased sex drive, irritated eyes</li> <li>5. Circulatory: hand-foot swelling, taste or smell changes, hair thinning or loss, constipation, lymphedema, numbness</li> <li>6. Sleep: frequent waking, early waking, difficulty falling asleep, vaginal discharge</li> <li>7. Hormonal: mood swings, depression, anxiety, nightmares, hot flashes, headaches, vaginal dryness</li> </ol>	
Wikman, A. <sup>67</sup>	402 Swedish patients with esophageal cancer	Cross-sectional  EORTC QLQ-OES-18 completed 6 months after surgery	PCA, HCA	<p>PCA and HCA solutions were identical except diarrhea formed a single symptom cluster using HCA; PCA solution was accepted.</p> <ol style="list-style-type: none"> <li>1. Fatigue/pain—fatigue, pain, insomnia, dyspnea</li> <li>2. Reflux/cough—dry mouth, taste changes, cough, reflux</li> <li>3. Eating difficulty—appetite loss, dysphagia, eating difficulty, nausea-vomiting</li> </ol>	The reflux/cough and eating difficulty symptom clusters were associated with increased risk of mortality

Table 5. Empirical Identification of Symptom Cluster Subgroups

Authors	Sample	Design	Method	Subgroups	Covariates/Patterns/Outcomes
Dirksen, et al. <sup>68</sup>	84 U.S. men with prostate cancer treated with radiotherapy	Longitudinal  Pre-treatment, post-treatment  Validated scales  Cluster: fatigue, insomnia, pain, depression, anxiety, treatment-related (sexuality, urinary, and bowel symptoms)	Latent Class Analysis (LCA)	Pre-treatment groups: 1. Resilient (45%)—all low symptoms 2. Adjusted (41%)—high treatment-related symptoms; low insomnia, depression, anxiety 3. Distressed (4%)—All high symptoms 4. Emerged (10%)—High fatigue, depression, anxiety; low treatment-related symptoms Post-treatment groups: • Groups 1-3 had similar results • Group 4 changed to “Impacted” (5%)—high pain, insomnia, depression, urinary, bowel symptoms	<ul style="list-style-type: none"> <li>All men in the emerging group before treatment moved to another group (66% moved to Distress).</li> <li>Among those whose group changed, there was a greater probability of changing to a group with higher symptom levels.</li> </ul>
Doong, et al. <sup>69</sup>	398 U.S. women with breast cancer about to undergo surgery	Cross-sectional  Pre-surgery  Validated Scales  Cluster: fatigue, pain, sleep disturbance, depressive symptoms	Latent Class Profile Analysis (LCPA)	1. All low symptoms (61%) 2. All high symptoms (7%) 3. Low pain, high fatigue (32%)	<ul style="list-style-type: none"> <li>Rare alleles of cytokine genes (IL6 rs2069845, IL13 rs1295686, TNF<math>\alpha</math> rs1800610) had increased odds of being in the all-high symptoms subgroup.</li> </ul>
Franceschini, et al. <sup>70</sup>	140 Brazilian Lung cancer patients	Cross-sectional  EORTC QLQ-C30; symptoms selected for analysis: fatigue,	HCA	1. Mild symptoms (60%) 2. Moderate symptoms (28%) 3. Severe symptoms (12%)	<ul style="list-style-type: none"> <li>Subgroups with more severe symptoms had poorer quality of life</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

		pain, insomnia, depression			
Husain, et al. <sup>71</sup>	221 U.S. patients with advanced cancer	Longitudinal  Study entry, weeks 2, 4, 8, 12  ESAS	Cluster Analysis	<ol style="list-style-type: none"> <li>1. High-- tired; Moderate-- drowsy, appetite, wellbeing, pain, depression, anxiety (25%)</li> <li>2. High-- tired; Moderate— drowsy appetite, wellbeing; Low—pain, depression, anxiety (31%)</li> <li>3. Low—tired, drowsy, appetite, wellbeing, pain, depression, anxiety (44%)</li> </ol>	<ul style="list-style-type: none"> <li>• Subgroup membership predicted quality of life over time</li> <li>• Grouping by symptom cluster profiles did not add predictive value to a widely used measure of performance status in palliative care</li> </ul>
Kim, et al. <sup>72</sup>	282 U.S. breast cancer patients treated with chemotherapy or radiotherapy	Longitudinal  Pre-treatment, during treatment, end of treatment  Some validated scales, some single items  Cluster: Depressed mood, cognitive disturbance, fatigue, insomnia, pain	HCA at each time point  Logistic regression	<p>Pre-treatment</p> <ol style="list-style-type: none"> <li>1. All low symptoms</li> <li>2. High fatigue, low pain</li> <li>3. High pain</li> <li>4. All high symptoms</li> </ol> <p>During-end of treatment</p> <ol style="list-style-type: none"> <li>5. High depressed mood, cognitive disturbance</li> <li>6. High fatigue, insomnia</li> </ol>	<ul style="list-style-type: none"> <li>• Subgroup membership changed substantially across time except for group 1.</li> <li>• Subgroup 4 (reference group) differed from the other groups on baseline performance status, symptom burden, and treatment modality; this pattern was consistent across time.</li> </ul>
Kim, et al. <sup>73</sup>	282 U.S. breast cancer patients treated with chemotherapy or radiotherapy	Longitudinal  Pre-treatment, during treatment, end of treatment  Some validated scales, some single items  Cluster:	HCA using symptom severity scores across three time points  Logistic regression	<ol style="list-style-type: none"> <li>1. Gradually increasing symptoms (26%)</li> <li>2. Constantly low symptoms (37%)</li> <li>3. Dramatic increase and decrease of symptoms (14%)</li> <li>4. Constantly high symptoms (13%)</li> <li>5. Initially high symptoms with dramatic decrease (10%)</li> </ol>	<ul style="list-style-type: none"> <li>• Antecedents that distinguished group 4 (reference group) from other groups: baseline performance status, previous treatment, and education</li> <li>• Subgroup 4 had worse functional limitations than other groups</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

		Depressed mood, cognitive disturbance, fatigue, insomnia, pain			
Liu, et al. <sup>74</sup>	76 U.S. women with breast cancer being treated with anthracycline-based chemotherapy	Longitudinal:  Pre-treatment, during each treatment cycle for 4 cycles (7 time points)  Validated scales Cluster: fatigue, sleep disturbance, depression	Mixed effects model  Independent variables: SCI  Dependent variables: individual symptom scores	Symptom Cluster Index (SCI) groups based on scale cut-offs: <ul style="list-style-type: none"> <li>• SCI0: no symptoms (20%)</li> <li>• SCI1: 1 symptom (28%)</li> <li>• SCI2: 2 symptoms (56%)</li> <li>• SCI3: 3 symptoms (24%).</li> </ul>	<ul style="list-style-type: none"> <li>• Subgroups with higher SCI prior to treatment had worse symptoms during treatment compared with lower SCI groups</li> <li>• Subgroups did not differ by demographic or clinical factors</li> </ul>
Reyes-Gibby, et al. <sup>75</sup>	599 U.S. newly diagnosed lung cancer patients	Cross-sectional  Prior to treatment  Single items:  Cluster: Pain, depressed mood, fatigue	HCA Logistic regression	<ol style="list-style-type: none"> <li>1. Severe symptoms (16%)</li> <li>2. Low intensity symptoms (30%)</li> <li>3. High pain; low depressed mood, fatigue</li> <li>4. High fatigue; low depressed mood, pain</li> <li>5. High fatigue depressed mood; low pain</li> </ol>	Comparison of subgroups 1 and 2: Additive effect of 5 alleles predicted membership in high symptom group controlling for disease stage and sex: <ul style="list-style-type: none"> <li>• ENOS -1474 T/A</li> <li>• IL1<math>\beta</math> T-31C</li> <li>• TNRR2 Met<sup>196</sup> Arg</li> <li>• PTGS2 exon10+8731&gt;C</li> <li>• IL1Or<math>\beta</math> Lys<sup>47</sup> Glu</li> </ul>
Sanford, et al. <sup>76</sup>	80 U.S. women with breast cancer being treated with chemotherapy	Longitudinal:  Pre-treatment, cycle 4 day 1, 6 months later  Validated symptom scales Cluster: fatigue, sleep, depression, anxiety, cognitive impairment	Correlation; Mixed effect models	SCI groups based on scale cut-offs: <ul style="list-style-type: none"> <li>• SCI0 (22%)</li> <li>• SCI1 (28%)</li> <li>• SCI2 (26%)</li> <li>• SCI3-5 (24%)</li> </ul>	<ul style="list-style-type: none"> <li>• Fatigue, depression, cognitive impairment: For each symptom, SCI groups had similar trajectories with symptoms worsening during treatment.</li> <li>• Sleep: There was no change in sleep within subjects or between groups.</li> <li>• Anxiety: SCI groups had similar trajectories with anxiety improving over time.</li> <li>• Higher SCI scores predicted poorer quality of life.</li> </ul>

Symptom Cluster Definition FINAL, 6-13-16

<p>Starkweather, et al.<sup>77</sup></p>	<p>128 U.S. women with breast cancer</p>	<p>Cross-sectional 4 weeks after breast surgery before chemotherapy  Validated scales  Cluster: fatigue, depression, pain</p>	<p>Cut-off scores, extreme discordant subgroup analysis, median split</p>	<p>Composite score: comparison of groups with scores in the top and bottom 20% of the sample  Extreme discordant scores: all symptoms above cut-off</p>	<ul style="list-style-type: none"> <li>• Using composite scores, high and low symptom groups differed on IL6 and IL7</li> <li>• Using discordant scores, groups differed on IL7</li> <li>• Using median split, groups differed on IL4 and IL5.</li> </ul>
--	--	---	---	---	---

## References

1. Dodd M, Janson S, Facione N, et al. Advancing the science of symptom management. *J. Adv. Nurs.* Mar 2001;33(5):668-676.
2. Barsevick AM. The elusive concept of the symptom cluster. *Oncology Nursing Forum Online.* Sep 2007;34(5):971-980.
3. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters research and their implications for quality of life assessment in patients with cancer. *Journal of the National Cancer Institute Monographs.* 2007;37:39-46.
4. Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: a review of the literature. *Current Oncology.* Oct 2007;14(5):173-179.
5. Skerman HM, Yates PM, Battistutta D, Skerman HM, Yates PM, Battistutta D. Multivariate methods to identify cancer-related symptom clusters. *Res. Nurs. Health.* Jun 2009;32(3):345-360.
6. Kirkova J, Aktas A, Walsh D, Davis MP. Cancer symptom clusters: clinical and research methodology. *J Palliat Med.* Oct 2011;14(10):1149-1166.
7. Kirkova J, Aktas A, Walsh D, Rybicki L, Davis MP. Consistency of symptom clusters in advanced cancer. *Am. J. Hosp. Palliat. Care.* Aug 2010;27(5):342-346.
8. Aktas A, Walsh D, Rybicki L. Symptom clusters: myth or reality? *Palliat. Med.* Jun 2010;24(4):373-385.
9. Chen E, Nguyen J, Cramarossa G, et al. Symptom clusters in patients with lung cancer: a literature review. *Expert Rev Pharmacoecon Outcomes Res.* Aug 2011;11(4):433-439.
10. Nguyen J, Cramarossa G, Bruner D, et al. A literature review of symptom clusters in patients with breast cancer. *Expert Rev Pharmacoecon Outcomes Res.* Oct 2011;11(5):533-539.
11. Cherwin CH. Gastrointestinal symptom representation in cancer symptom clusters: a synthesis of the literature. *Oncol. Nurs. Forum.* Mar 2012;39(2):157-165.
12. Thavarajah N, Chen E, Zeng L, et al. Symptom clusters in patients with metastatic cancer: a literature review. *Expert Rev Pharmacoecon Outcomes Res.* Oct 2012;12(5):597-604.
13. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: Concept analysis and clinical implications for Cancer Nursing. *Cancer Nurs.* 2005;28(4):270-282.
14. Dodd M, Miaskowski C, Lee KA. Occurrence of symptom clusters. *Journal of the National Cancer Institute Monographs.* 2004;2004(32):76-78.
15. *Webster's Third New International Dictionary of the English Language, Unabridged.* Springfield, MA: Merriam-Webster, Inc.; 1986.
16. Jimenez A, Madero R, Alonso A, et al. Symptom clusters in advanced cancer. *J. Pain Symptom Manage.* Jul 2011;42(1):24-31.
17. Chen ML, Tseng HC. Symptom clusters in cancer patients. *Support. Care Cancer.* Aug 2006;14(8):825-830.
18. Chen E, Khan L, Zhang L, et al. Symptom clusters in patients with bone metastases--a reanalysis comparing different statistical methods. *Support. Care Cancer.* Nov 2012;20(11):2811-2820.
19. Fan G, Hadi S, Chow E, Fan G, Hadi S, Chow E. Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. *Supportive Cancer Therapy.* May 1 2007;4(3):157-162.
20. Maguire R, Stoddart K, Flowers P, McPhelim J, Kearney N. An Interpretative Phenomenological Analysis of the lived experience of multiple concurrent symptoms in patients with lung cancer: a contribution to the study of symptom clusters. *Eur J Oncol Nurs.* Jun 2014;18(3):310-315.
21. Molassiotis A, Lowe M, Blackhall F, Lorigan P. A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue. *Lung Cancer.* Jan 2011;71(1):94-102.
22. Lopez V, Copp G, Brunton L, Molassiotis A. Symptom experience in patients with gynecological cancers: the development of symptom clusters through patient narratives. *J Support Oncol.* Mar-Apr 2011;9(2):64-71.
23. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. *Cancer.* Dec 15 2013;119(24):4333-4340.
24. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. *J. Clin. Oncol.* Dec 1 2012;30(34):4249-4255.
25. Chera BS, Eisbruch A, Murphy BA, et al. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. *J. Natl. Cancer Inst.* Jul 2014;106(7).
26. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. *J. Natl. Cancer Inst.* Jul 2014;106(7).



Symptom Cluster Definition FINAL, 6-13-16

27. Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C. A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies. *Cancer Nurs*. Feb 18 2016.
28. Cooley ME, Siefert ML. Assessment of multiple co-occurring cancer symptoms in the clinical setting. *Semin. Oncol. Nurs*. 2016;32(4):361-372.
29. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: An update. *Advances in Nursing Science*. 1997;19(3):14-27.
30. Jim HS, Jacobsen PB, Phillips KM, Wenham RM, Roberts W, Small BJ. Lagged relationships among sleep disturbance, fatigue, and depressed mood during chemotherapy. *Health Psychol*. Jul 2013;32(7):768-774.
31. Parker KP, Kimble LP, Dunbar SB, Clark PC. Symptom interactions as mechanisms underlying symptom pairs and clusters. *Journal of Nursing Scholarship*. 2005;37(3):209-215.
32. Humphreys J, Lee KA, Carrieri-Kohlman V, et al. Theory of symptom management. In: Smith JJ, Liehr PR, eds. *Middle Range Theory for Nursing* New York: Springer; 2008:145-158.
33. Henly SJ, Kallas KD, Klatt CM, Swenson KK. The notion of time in symptom experiences. *Nurs. Res*. Nov-Dec 2003;52(6):410-417.
34. Brant JM, Beck S, Miaskowski C. Building dynamic models and theories to advance the science of symptom management research. *J. Adv. Nurs*. 2009;66(1):228-240.
35. Olver IN, Elliott JA, Koczwara B. A qualitative study investigating chemotherapy-induced nausea as a symptom cluster. *Support. Care Cancer*. Oct 2014;22(10):2749-2756.
36. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. *Ann. N. Y. Acad. Sci*. Mar 2001;933:222-234.
37. Dantzer R, Kelley KW, Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. *Brain. Behav. Immun*. Feb 2007;21(2):153-160.
38. Ho SY, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. *J. Pain Symptom Manage*. Apr 2015;49(4):707-715.
39. Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. *Crit. Rev. Oncol. Hematol*. May 2011;78(2):127-137.
40. Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. *Oncol. Nurs. Forum*. Jul 2007;34(4):785-792.
41. Lin S, Chen Y, Yang L, Zhou J. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. *J. Clin. Nurs*. May 2013;22(9-10):1281-1290.
42. So WK, Marsh G, Ling WM, et al. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. *Oncol. Nurs. Forum*. Jul 2009;36(4):E205-214.
43. Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong JC, Houts AC. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. *Journal of Clinical Sleep Medicine*. 2009;5(2):132-136.
44. Oh H, Seo Y, Jeong H, Seo W. The identification of multiple symptom clusters and their effects on functional performance in cancer patients. *J. Clin. Nurs*. Oct 2012;21(19-20):2832-2842.
45. Brown JK, Cooley ME, Chernecky C, Sarna L. A symptom cluster and sentinel symptom experienced by women with lung cancer. *Oncol. Nurs. Forum*. Nov 1 2011;38(6):E425-435.
46. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. *Support. Care Cancer*. Sep 2009;17(9):1223-1230.
47. Cheung WY, Le LW, Gagliese L, Zimmermann C. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. *Support. Care Cancer*. Mar 24 2010.
48. Gleason JF, Jr., Case D, Rapp SR, et al. Symptom clusters in patients with newly-diagnosed brain tumors. *The Journal of Supportive Oncology*. 2007 Oct;5(9):427-433.
49. Huang J, Gu L, Zhang L, Lu X, Zhuang W, Yang Y. Symptom Clusters in Ovarian Cancer Patients With Chemotherapy After Surgery: A Longitudinal Survey. *Cancer Nurs*. Mar-Apr 2016;39(2):106-116.
50. Kenne Sarenmalm E, Browall M, Gaston-Johansson F. Symptom burden clusters: a challenge for targeted symptom management. A longitudinal study examining symptom burden clusters in breast cancer. *J. Pain Symptom Manage*. Apr 2014;47(4):731-741.
51. Kim E, Jahan T, Aouizerat BE, et al. Changes in symptom clusters in patients undergoing radiation therapy. *Support. Care Cancer*. Nov 2009;17(11):1383-1391.
52. Kim HJ, Barsevick AM, Tulman L, et al. Treatment-related symptom clusters in breast cancer: a secondary analysis. *J. Pain Symptom Manage*. Nov 2008;36(5):468-479.
53. Walsh D, Rybicki L. Symptom clustering in advanced cancer. *Support. Care Cancer*. Aug 2006;14(8):831-836.
54. Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. *J. Pain Symptom Manage*. May 2010;39(5):847-858.

## Symptom Cluster Definition FINAL, 6-13-16

55. Olson K, Hayduk L, Cree M, et al. The changing causal foundations of cancer-related symptom clustering during the final month of palliative care: a longitudinal study. *BMC Med Res Methodol.* 2008;8:36.
56. Pirri C, Bayliss E, Trotter J, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. *Support. Care Cancer.* Mar 2013;21(3):735-748.
57. Skerman HM, Yates PM, Battistutta D. Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. *Support. Care Cancer.* Jan 2012;20(1):95-105.
58. Tsai JS, Wu CH, Chiu TY, Chen CY. Significance of symptom clustering in palliative care of advanced cancer patients. *J. Pain Symptom Manage.* Apr 2010;39(4):655-662.
59. Tabachnick BG, Fidell LS. *Using multivariate statistics.* 5th ed. Boston: Pearson/Allyn & Bacon; 2007.
60. Henoeh I, Ploner A, Tishelman C. Increasing stringency in symptom cluster research: a methodological exploration of symptom clusters in patients with inoperable lung cancer. *Oncol. Nurs. Forum.* Nov 2009;36(6):E282-292.
61. Munro BH, Visintainer MA, Page EB. *Statistical Methods for Health Care Research.* Philadelphia: J. B. Lippincott Company; 1986.
62. Chen E, Nguyen J, Khan L, et al. Symptom clusters in patients with advanced cancer: a reanalysis comparing different statistical methods. *J. Pain Symptom Manage.* Jul 2012;44(1):23-32.
63. Cheville AL, Novotny PJ, Sloan JA, et al. Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer. *J. Pain Symptom Manage.* Aug 2011;42(2):202-212.
64. Cheville AL, Novotny PJ, Sloan JA, et al. The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. *J. Pain Symptom Manage.* Aug 2011;42(2):213-221.
65. Maliski SL, Kwan L, Elashoff D, et al. Symptom clusters related to treatment for prostate cancer. *Oncology Nursing Forum Online.* Sep 2008;35(5):786-793.
66. Roiland RA, Heidrich SM. Symptom clusters and quality of life in older adult breast cancer survivors. *Oncol. Nurs. Forum.* Nov 1 2011;38(6):672-680.
67. Wikman A, Johar A, Lagergren P. Presence of symptom clusters in surgically treated patients with esophageal cancer: implications for survival. *Cancer.* Jan 15 2014;120(2):286-293.
68. Dirksen SR, Belyea MJ, Wong W, Epstein DR. Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy. *Cancer Nurs.* Feb 27 2015.
69. Doong SH, Dhruva A, Dunn LB, et al. Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. *Biol Res Nurs.* May 2015;17(3):237-247.
70. Franceschini J, Jardim JR, Fernandes AL, Jamnik S, Santoro IL. Relationship between the magnitude of symptoms and the quality of life: a cluster analysis of lung cancer patients in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia.* Jan-Feb 2013;39(1):23-31.
71. Husain A, Myers J, Selby D, Thomson B, Chow E. Subgroups of advanced cancer patients clustered by their symptom profiles: quality-of-life outcomes. *J Palliat Med.* Nov 2011;14(11):1246-1253.
72. Kim HJ, McDermott PA, Barsevick AM. Comparison of groups with different patterns of symptom cluster intensity across the breast cancer treatment trajectory. *Cancer Nurs.* Mar-Apr 2014;37(2):88-96.
73. Kim HJ, Barsevick AM, Beck SL, Dudley W. Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer: a secondary analysis. *Oncol. Nurs. Forum.* Jan 2012;39(1):E20-30.
74. Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. *Psychooncology.* Feb 2009;18(2):187-194.
75. Reyes-Gibby CC, Swartz MD, Yu X, et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. *Support. Care Cancer.* Nov 2013;21(11):3117-3125.
76. Sanford SD, Beaumont JL, Butt Z, Sweet JJ, Cella D, Wagner LI. Prospective longitudinal evaluation of a symptom cluster in breast cancer. *J. Pain Symptom Manage.* Apr 2014;47(4):721-730.
77. Starkweather AR, Lyon DE, Elswick RK, Jr., Montpetit A, Conley Y, McCain NL. Symptom Cluster Research in Women with Breast Cancer: A Comparison of Three Subgrouping Techniques. *Adv Breast Cancer Res.* Oct 2013;2(4):107-113.